What is the role of colchicine in the treatment of AA (inflammatory) amyloidosis?

Updated: Aug 11, 2020
  • Author: Richa Dhawan, MD, CCD; Chief Editor: Herbert S Diamond, MD  more...
  • Print
Answer

The lack of currently available agents that directly target amyloid deposits mandates the use of agents that strongly suppress the inflammation caused by the primary disease. At present, the major therapeutic strategy in amyloid A (AA) amyloidosis is treatment of the primary inflammatory disease in order to reduce the circulating levels of the amyloid precursor protein, serum amyloid A (SAA). Intensive treatment that lowers SAA levels to less than 10 mg/L may halt disease progression and induce a slow progressive recovery of renal function. Biologic agents, including tumor necrosis factor (TNF) inhibitors and interleukin-1 (IL-1) and IL-6 antagonists, are the main therapeutic options used for this purpose.,

The major consequence of renal amyloidosis is complete renal failure. Inpatient care may be necessary for intercurrent infections or deterioration in renal function, requiring acute dialysis or the initiation of chronic dialysis. 


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!